BERLIN—German pharmaceutical company BioNTech is confident that its coronavirus vaccine, which was developed together with the U.S. company Pfizer, works against the new UK variant, but further studies are needed, its chief executive said on Dec. 22.
The variant, detected mainly in London and the southeast of England in recent weeks, has sparked concern worldwide because of signs that it may spread more easily. While there is no indication it causes more serious illness, numerous countries in Europe and beyond have restricted travel from the UK as a result.
